What is claimed is:

1. A method of neutralizing infectious Ebola virus (EBOV), the method comprising exposing a cell infected with EBOV to a composition comprising three anti-EBOV antibodies or antigen-binding fragments thereof, wherein:

(a) a first anti-EBOV antibody or antigen-binding fragment thereof comprises a heavy chain complementarity determining region 1 (HCDR)1 amino acid sequence as set forth in SEQ ID NO: 20 with no more than one amino acid substitution; an HCDR2 amino acid sequence as set forth in SEQ ID NO: 22 with no more than one amino acid substitution; an HCDR3 amino acid sequence as set forth in SEQ ID NO: 24 with no more than one amino acid substitution; a light chain complementarity determining region (LCDR)1 amino acid sequence as set forth in SEQ ID NO: 28 with no more than one amino acid substitution; an LCDR2 amino acid sequence as set forth in SEQ ID NO: 30 with no more than one amino acid substitution; and an LCDR3 amino acid sequence as set forth in SEQ ID NO: 32 with no more than one amino acid substitution;

(b) a second anti-EBOV antibody or antigen-binding fragment thereof comprises an HCDR1 amino acid sequence of SEQ ID NO: 68 with no more than one amino acid substitution; an HCDR2 amino acid sequence of SEQ ID NO: 70 with no more than one amino acid substitution; an HCDR3 amino acid sequence of SEQ ID NO: 72 with no more than one amino acid substitution; an LCDR1 amino acid sequence of SEQ ID NO: 76 with no more than one amino acid substitution; an LCDR2 amino acid sequence of SEQ ID NO: 78 with no more than one amino acid substitution; and an LCDR3 amino acid sequence of SEQ ID NO: 80 with no more than one amino acid substitution; or

(c) a third anti-EBOV antibody or antigen-binding fragment thereof comprises an HCDR1 amino acid sequence of SEQ ID NO: 148 with no more than one amino acid substitution; an HCDR2 amino acid sequence of SEQ ID NO: 150 with no more than one amino acid substitution; an HCDR3 amino acid sequence of SEQ ID NO: 152 with no more than one amino acid substitution; an LCDR1 amino acid sequence of SEQ ID NO: 156 with no more than one amino acid substitution; an LCDR2 amino acid sequence of SEQ ID NO: 158 with no more than one amino acid substitution; and an LCDR3 amino acid sequence of SEQ ID NO: 160 with no more than one amino acid substitution.

2. The method of claim 1, wherein the composition comprises:

(a) a first anti-EBOV antibody or antigen-binding fragment thereof comprising a heavy chain variable region (HCVR) amino acid sequence having 95% sequence identity to SEQ ID NO: 18; and a light chain variable region (LCVR) amino acid sequence having 95% sequence identity to SEQ ID NO: 26;

(b) a second anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 95% sequence identity to SEQ ID NO: 66; and an LCVR amino acid sequence having 95% sequence identity to SEQ ID NO: 74; or

(c) a third anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 95% sequence identity to SEQ ID NO: 146; and an LCVR amino acid sequence having 95% sequence identity to SEQ ID NO: 154.

3. The method of claim 1, wherein the composition comprises:

(a) a first anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 18; and an LCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 26;

(b) a second anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 66; and an LCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 74; or

(c) a third anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 146; and an LCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 154.

4. The method of claim 1, wherein the composition comprises:

(a) a first anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 18; and an LCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 26;

(b) a second anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 66; and an LCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 74; or

(c) a third anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 146; and an LCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 154.

5. The method of claim 1, wherein the composition comprises:

a first anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR having an amino acid sequence of SEQ ID NO: 18 with no more than 3 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 26 with no more than 3 amino acid substitutions.

6. The method of claim 1, wherein the composition comprises:

a second anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR having an amino acid sequence of SEQ ID NO: 66 with no more than 3 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 74 with no more than 3 amino acid substitutions.

7. The method of claim 1, wherein the composition comprises:

a third anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR having an amino acid sequence of SEQ ID NO: 146 with no more than 3 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 154 with no more than 3 amino acid substitutions.

8. The method of claim 1, wherein the composition comprises:

a first anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR having an amino acid sequence of SEQ ID NO: 18 with no more than 2 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 26 with no more than 2 amino acid substitutions.

9. The method of claim 1, wherein the composition comprises:

a second anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR having an amino acid sequence of SEQ ID NO: 66 with no more than 2 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 74 with no more than 2 amino acid substitutions.

10. The method of claim 1, wherein the composition comprises:

a third anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR having an amino acid sequence of SEQ ID NO: 146 with no more than 2 amino acid

substitutions; and an LCVR amino acid sequence of SEQ ID NO: 154 with no more than 2 amino acid substitutions.

11. The method of claim 1, wherein the infectious EBOV is neutralized in vitro or in vivo.

12. The method of claim 1, wherein the composition is used in combination with one or more additional therapeutic agents or anti-EBOV treatment modalities.

13. The method of claim 12, wherein the one or more additional therapeutic agents is selected from the group consisting of an anti-viral drug, an anti-inflammatory drug, a different antibody to EBOV, a vaccine for EBOV, TKM Ebola, brincidofovir, favipiravir, BCX-4430, AVI-7537 and interferons.

14. The method of claim 12, wherein the one or more additional therapeutic agents comprise one or more anti-EBOV antibodies.

15. The method of claim 1, wherein the virus is neutralized in vivo and the composition is to be administered subcutaneously, intravenously, intradermally, intramuscularly, intranasally, or orally to the subject in need thereof.

16. The method of claim 13, wherein the anti-inflammatory is a corticosteroid or non-steroidal anti-inflammatory drug.

17. Use of at least one antibody or antigen-binding fragment thereof, or a pharmaceutically acceptable composition comprising the at least one antibody or antigen-binding fragment thereof, in the manufacture of a medicament for treating or ameliorating at least one symptom of EBOV infection, or of decreasing the frequency or severity of at least one symptom of EBOV infection,

wherein the at least one antibody or antigen-binding fragment thereof is to be administered to a subject in need thereof,

wherein the at least one antibody or antigen-binding fragment thereof comprises:

(a) a heavy chain complementarity determining region 1 (HCDR)1 amino acid sequence as set forth in SEQ ID NO: 20 with no more than one amino acid substitution; an

HCDR2 amino acid sequence as set forth in SEQ ID NO: 22 with no more than one amino acid substitution; an HCDR3 amino acid sequence as set forth in SEQ ID NO: 24 with no more than one amino acid substitution; a light chain complementarity determining region (LCDR)1 amino acid sequence as set forth in SEQ ID NO: 28 with no more than one amino acid substitution; an LCDR2 amino acid sequence as set forth in SEQ ID NO: 30 with no more than one amino acid substitution; and an LCDR3 amino acid sequence as set forth in SEQ ID NO: 32 with no more than one amino acid substitution;

(b) an HCDR1 amino acid sequence of SEQ ID NO: 68 with no more than one amino acid substitution; an HCDR2 amino acid sequence of SEQ ID NO: 70 with no more than one amino acid substitution; an HCDR3 amino acid sequence of SEQ ID NO: 72 with no more than one amino acid substitution; an LCDR1 amino acid sequence of SEQ ID NO: 76 with no more than one amino acid substitution; an LCDR2 amino acid sequence of SEQ ID NO: 78 with no more than one amino acid substitution; and an LCDR3 amino acid sequence of SEQ ID NO: 80 with no more than one amino acid substitution; or

(c) an HCDR1 amino acid sequence of SEQ ID NO: 148 with no more than one amino acid substitution; an HCDR2 amino acid sequence of SEQ ID NO: 150 with no more than one amino acid substitution; an HCDR3 amino acid sequence of SEQ ID NO: 152 with no more than one amino acid substitution; an LCDR1 amino acid sequence of SEQ ID NO: 156 with no more than one amino acid substitution; an LCDR2 amino acid sequence of SEQ ID NO: 158 with no more than one amino acid substitution; and an LCDR3 amino acid sequence of SEQ ID NO: 160 with no more than one amino acid substitution,

18. The use of claim 17, comprising an antibody cocktail comprising a mixture of at least two anti-EBOV antibodies to be administered.

19. The use of claim 18, wherein the antibody cocktail comprises:

(a) a first anti-EBOV antibody or antigen-binding fragment thereof comprising a heavy chain variable region (HCVR) amino acid sequence having 95% sequence identity to SEQ ID NO: 18; and a light chain variable region (LCVR) amino acid sequence having 95% sequence identity to SEQ ID NO: 26;

(b) a second anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 95% sequence identity to SEQ ID NO: 66; and an LCVR amino acid sequence having 95% sequence identity to SEQ ID NO: 74; or

(c) a third anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 95% sequence identity to SEQ ID NO: 146; and an LCVR amino acid sequence having 95% sequence identity to SEQ ID NO: 154.

20. The use of claim 18, wherein the antibody cocktail comprises:

(a) a first anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 18; and an LCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 26;

(b) a second anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 66; and an LCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 74; or

(c) a third anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 146; and an LCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 154.

21. The use of claim 18, wherein the antibody cocktail comprises:

(a) a first anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 18; and an LCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 26

(b) a second anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 66; and an LCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 74; or

(c) a third anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 146; and an LCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 154.

22. The use of claim 18, wherein the antibody cocktail comprises:

a first anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR having an amino acid sequence of SEQ ID NO: 18 with no more than 3 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 26 with no more than 3 amino acid substitutions.

23. The use of claim 18, wherein the antibody cocktail comprises:

a second anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR having an amino acid sequence of SEQ ID NO: 66 with no more than 3 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 74 with no more than 3 amino acid substitutions.

24. The use of claim 18, wherein the antibody cocktail comprises:

a third anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR having an amino acid sequence of SEQ ID NO: 146 with no more than 3 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 154 with no more than 3 amino acid substitutions.

25. The use of claim 18, wherein the antibody cocktail comprises:

a first anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR having an amino acid sequence of SEQ ID NO: 18 with no more than 2 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 26 with no more than 2 amino acid substitutions.

26. The use of claim 18, wherein the antibody cocktail comprises:

a second anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR having an amino acid sequence of SEQ ID NO: 66 with no more than 2 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 74 with no more than 2 amino acid substitutions.

27. The use of claim 18, wherein the antibody cocktail comprises:

a third anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR having an amino acid sequence of SEQ ID NO: 146 with no more than 2 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 154 with no more than 2 amino acid substitutions.

28. The use of claim 17, wherein the at least one symptom is selected from the group consisting of fever, headache, fatigue, loss of appetite, myalgia, diarrhea, vomiting, abdominal pain, dehydration and unexplained bleeding.

29. The use of claim 17, wherein the pharmaceutical composition is to be administered prophylactically or therapeutically to the subject in need thereof.

30. The use of claim 17, wherein the antibody or antigen-binding fragment thereof, or the pharmaceutical composition comprising the antibody or antigen-binding fragment thereof is to be administered in combination with a second therapeutic agent.

31. The use of claim 30, wherein the second therapeutic agent is selected from the group consisting of an anti-viral drug, an anti-inflammatory drug, a different antibody to EBOV, a vaccine for EBOV, small interfering RNAs that target viral RNA polymerase, brincidofovir, favipiravir, BCX-4430, antisense phosphorodiamidate morpholino oligomers that target Ebola virus VP24 gene, and interferons.

32. The use of claim 31, wherein the second therapeutic agent is an anti-inflammatory selected from corticosteroids and non-steroidal anti-inflammatory drugs.

33. The use of claim 18, wherein the antibody or antigen-binding fragment thereof, or the pharmaceutical composition comprising the antibody or antigen-binding fragment thereof is to be administered subcutaneously, intravenously, intradermally, intramuscularly, intranasally, or orally.

34. Use of at least one anti-EBOV antibody or antigen-binding fragment thereof, or a pharmaceutical composition comprising at least one anti-EBOV antibody or antigen-binding fragment thereof, in the manufacture of a medicament for increasing survival, or the likelihood of survival of a subject suffering from infection with Ebola Virus (EBOV), or a subject exposed to EBOV, or at risk for exposure to, or for acquiring EBOV,

wherein the at least one anti-EBOV antibody or antigen-binding fragment thereof, or a pharmaceutical composition comprising at least one anti-EBOV antibody or antigen-binding fragment thereof is to be administered to a subject in need thereof,

wherein the antibody or antigen-binding fragment thereof comprises:

(a) a heavy chain complementarity determining region 1 (HCDR)1 amino acid sequence as set forth in SEQ ID NO: 20 with no more than one amino acid substitution; an HCDR2 amino acid sequence as set forth in SEQ ID NO: 22 with no more than one amino

acid substitution; an HCDR3 amino acid sequence as set forth in SEQ ID NO: 24 with no more than one amino acid substitution; a light chain complementarity determining region (LCDR)1 amino acid sequence as set forth in SEQ ID NO: 28 with no more than one amino acid substitution; an LCDR2 amino acid sequence as set forth in SEQ ID NO: 30 with no more than one amino acid substitution; and an LCDR3 amino acid sequence as set forth in SEQ ID NO: 32 with no more than one amino acid substitution;

(b) an HCDR1 amino acid sequence of SEQ ID NO: 68 with no more than one amino acid substitution; an HCDR2 amino acid sequence of SEQ ID NO: 70 with no more than one amino acid substitution; an HCDR3 amino acid sequence of SEQ ID NO: 72 with no more than one amino acid substitution; an LCDR1 amino acid sequence of SEQ ID NO: 76 with no more than one amino acid substitution; an LCDR2 amino acid sequence of SEQ ID NO: 78 with no more than one amino acid substitution; and an LCDR3 amino acid sequence of SEQ ID NO: 80 with no more than one amino acid substitution; or

(c) an HCDR1 amino acid sequence of SEQ ID NO: 148 with no more than one amino acid substitution; an HCDR2 amino acid sequence of SEQ ID NO: 150 with no more than one amino acid substitution; an HCDR3 amino acid sequence of SEQ ID NO: 152 with no more than one amino acid substitution; an LCDR1 amino acid sequence of SEQ ID NO: 156 with no more than one amino acid substitution; an LCDR2 amino acid sequence of SEQ ID NO: 158 with no more than one amino acid substitution; and an LCDR3 amino acid sequence of SEQ ID NO: 160 with no more than one amino acid substitution.

35. The use of claim 34, comprising an antibody cocktail comprising a mixture of at least two anti-EBOV antibodies to be administered.

36. The use of claim 35, wherein the antibody cocktail comprises:

(a) a first anti-EBOV antibody or antigen-binding fragment thereof comprising a heavy chain variable region (HCVR) amino acid sequence having 95% sequence identity to SEQ ID NO: 18; and a light chain variable region (LCVR) amino acid sequence having 95% sequence identity to SEQ ID NO: 26;

(b) a second anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 95% sequence identity to SEQ ID NO: 66; and an LCVR amino acid sequence having 95% sequence identity to SEQ ID NO: 74; or

(c) a third anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 95% sequence identity to SEQ ID NO: 146; and an LCVR amino acid sequence having 95% sequence identity to SEQ ID NO: 154.

37. The use of claim 35, wherein the antibody cocktail comprises:

(a) a first anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 18; and an LCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 26;

(b) a second anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 66; and an LCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 74; or

(c) a third anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 146; and an LCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 154.

38. The use of claim 35, wherein the antibody cocktail comprises:

(a) a first anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 18; and an LCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 26;

(b) a second anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 66; and an LCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 74; or

(c) a third anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 146; and an LCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 154.

39. The use of claim 35, wherein the antibody cocktail comprises:

a first anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR having an amino acid sequence of SEQ ID NO: 18 with no more than 3 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 26 with no more than 3 amino acid substitutions.

40. The use of claim 35, wherein the antibody cocktail comprises:

a second anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR having an amino acid sequence of SEQ ID NO: 66 with no more than 3 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 74 with no more than 3 amino acid substitutions.

41. The use of claim 35, wherein the antibody cocktail comprises:

a third anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR having an amino acid sequence of SEQ ID NO: 146 with no more than 3 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 154 with no more than 3 amino acid substitutions.

42. The use of claim 35, wherein the antibody cocktail comprises:

a first anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR having an amino acid sequence of SEQ ID NO: 18 with no more than 2 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 26 with no more than 2 amino acid substitutions.

43. The use of claim 35, wherein the antibody cocktail comprises:

a second anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR having an amino acid sequence of SEQ ID NO: 66 with no more than 2 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 74 with no more than 2 amino acid substitutions.

44. The use of claim 35, wherein the antibody cocktail comprises:

a third anti-EBOV antibody or antigen-binding fragment thereof comprising an HCVR having an amino acid sequence of SEQ ID NO: 146 with no more than 2 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 154 with no more than 2 amino acid substitutions.

45. The use of claim 34, wherein the antibody or antigen-binding fragment thereof, or the pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, or an antibody cocktail comprising a mixture of at least two antibodies, is to be administered prophylactically or therapeutically to the subject in need thereof.

46. The use of claim 34, wherein the subject in need thereof who is at risk for exposure to, or for acquiring an EBOV infection is selected from the group consisting of an immunocompromised individual, a healthcare worker, a person who is suspected of having been exposed to a person harboring the Ebola virus, a person who comes into physical contact or close physical proximity with an infected individual, a hospital employee, a pharmaceutical researcher, maintenance personnel responsible for cleaning a hospital facility or institution where an Ebola patient has been treated, individuals who have visited or are planning to visit an area or country known to have or suspected to have an outbreak of Ebola virus and a frequent flyer.

47. The use of claim 35, wherein the antibody or antigen-binding fragment thereof, or the pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, or the antibody cocktail is to be administered in combination with a second therapeutic agent.

48. The use of claim 47, wherein the second therapeutic agent is selected from the group consisting of an anti-viral drug, an anti-inflammatory drug, a different antibody to EBOV, a vaccine for EBOV, small interfering RNAs that target viral RNA polymerase, brincidofovir, favipiravir antisense phosphorodiamidate morpholino oligomers that target Ebola virus VP24 gene, and interferons.

49. The use of claim 47, wherein the second therapeutic agent is an anti-inflammatory selected from corticosteroids and non-steroidal anti-inflammatory drugs.

50. The use of claim 47, wherein the second therapeutic agent is selected from the group consisting of TKM Ebola, CMX-001, T-705, BCX-4430, and AVI-7537.

51. The use of claim 34, wherein the pharmaceutical composition is to be administered subcutaneously, intravenously, intradermally, intramuscularly, intranasally, or orally.

52. The use of claim 34, wherein the subject is one for whom a vaccine is contra-indicated, or for whom a vaccine is less efficacious.

53. The use of claim 34, wherein the subject is elderly or very young.

54. The use of claim 34, wherein the subject is free of infection or has reduced or no viral titers at the time of the antibody or antigen-binding fragment thereof to be administered.

55. The use of claim 34, wherein the subject is exposed to EBOV by physical contact or close physical proximity with an infected individual.

56. The use of claim 34, wherein the subject is a hospital worker in an area or country known to have or suspected to have an outbreak of EBOV.

57. The use of claim 34, wherein the EBOV is a Zaire strain.